Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) traded up 3.4% during trading on Wednesday . The company traded as high as $89.90 and last traded at $89.48, with a volume of 629,546 shares. The stock had previously closed at $86.51.

A number of equities research analysts have recently commented on the stock. Vetr downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating and set a $94.38 price target for the company. in a report on Tuesday, May 31st. BMO Capital Markets assumed coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, April 7th. They issued a “market perform” rating and a $90.00 target price on the stock. Credit Suisse Group AG reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, June 16th. Jefferies Group reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 31st. Finally, Maxim Group reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Thursday. Eight equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $125.11.

The company’s market capitalization is $22.14 billion. The firm has a 50 day moving average of $88.81 and a 200-day moving average of $90.49.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Wednesday, April 27th. The pharmaceutical company reported $0.09 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.29 by $0.20. The business had revenue of $398.10 million for the quarter, compared to analyst estimates of $439.94 million. Vertex Pharmaceuticals’s revenue was up 187.4% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.62) earnings per share. On average, analysts forecast that Vertex Pharmaceuticals Inc. will post $1.10 EPS for the current fiscal year.

In related news, SVP Paul M. Silva sold 3,000 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, May 9th. The shares were sold at an average price of $87.63, for a total transaction of $262,890.00. Following the transaction, the senior vice president now directly owns 15,950 shares of the company’s stock, valued at $1,397,698.50. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Joshua S. Boger sold 5,130 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, April 13th. The shares were sold at an average price of $84.27, for a total transaction of $432,305.10. Following the transaction, the director now directly owns 270,414 shares in the company, valued at $22,787,787.78. The disclosure for this sale can be found here.

Other institutional investors have modified their holdings of the company. Ameritas Investment Partners Inc. raised its position in shares of Vertex Pharmaceuticals by 0.9% in the fourth quarter. Ameritas Investment Partners Inc. now owns 8,698 shares of the pharmaceutical company’s stock valued at $1,094,000 after buying an additional 78 shares during the last quarter. Turner Investments L.P. acquired a new position in shares of Vertex Pharmaceuticals during the fourth quarter valued at about $1,095,000. Robeco Institutional Asset Management B.V. raised its position in shares of Vertex Pharmaceuticals by 32.1% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 10,728 shares of the pharmaceutical company’s stock valued at $1,350,000 after buying an additional 2,605 shares during the last quarter. Greenwood Capital Associates LLC raised its position in shares of Vertex Pharmaceuticals by 0.7% in the fourth quarter. Greenwood Capital Associates LLC now owns 10,768 shares of the pharmaceutical company’s stock valued at $1,355,000 after buying an additional 80 shares during the last quarter. Finally, Gratus Capital LLC acquired a new position in shares of Vertex Pharmaceuticals during the fourth quarter valued at about $1,858,000.

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.